Cytokines as a link between innate and adaptive antitumor immunity

Trends in Immunology

Volumn 23, Issue 4, 2002, Pages 201-208

  Belardelli, Filippo ^a   Ferrantini, Maria ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER ADJUVANT THERAPY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MACROPHAGE; NONHUMAN; REVIEW; TH1 CELL; TUMOR IMMUNITY; VACCINATION;

AGING; ANIMALS; CELL COMMUNICATION; CYTOKINES; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; INTERFERONS; INTERLEUKIN-12; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 0036533489     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)02195-6     Document Type: Review

References (64)

1. Cytokines in innate and adaptive immunity
2. The host-tumor immune conflict: From immunosuppression to resistance and destruction
3. Dendritic cells and the control of immunity
4. A listing of human tumor antigens recognized by T cells
5. A fresh look at tumor immunosurveillance and immunotherapy
6. + mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: Relevance to hepatocarcinogenesis
7. Dendritic cells and tumor immunity
8. IFN-γ production by antigen-presenting cells: Mechanisms emerge
9. Type I IFNs enhance the terminal differentiation of dendritic cells
10. Type I interferon as a powerful adjuvant for monocyte-derived dendritic-cell development and activity in vitro and in Hu-PBL-SCID mice
11. Expression of CCR-7, MIP-3β and Th1 chemokines in type I IFN-induced monocyte-derived dendritic cells: Importance for the rapid acquisition of potent migratory and functional activities
12. Type I interferons and IL-12: Convergence and cross-regulation among mediators of cellular immunity
13. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo
14. Selective expression of an interleukin-12 receptor component by human T helper 1 cells
15. Interferon α and β as immune regulators - A new look
16. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA or lipopolysaccharide and promotes dendritic-cell activation
17. Role of interferons and other cytokines in the regulation of the immune response
18. Interleukin-1β induces tumor necrosis and early morphologic and metabolic changes in transplantable mouse tumors. Similarities with the anti-tumor effects of tumor necrosis factor α or β
19. Cytokines and their effects on maturation, differentiation and migration of dendritic cells
20. Inducible IL-2 production by dendritic cells revealed by global gene-expression analysis
21. IFN-γ expression in macrophages and its possible biological significance
22. Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors
23. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development
24. Interleukin-12: Basic principles and clinical applications
25. Specific and nonspecific immunity in the prevention of spontaneous tumours
26. IL-12 gene therapy for cancer: In synergy with other immunotherapies
27. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons
28. The neglected role of type I interferon in the T-cell response: Implications for its clinical use
29. Host humoral and cellular mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon α/β treatment in mice
30. Gene therapy of cancer with interferon: Lessons from tumor models and perspectives for clinical applications
31. Effect of IFN-α on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma
32. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
33. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia
34. The nature of the principal type I interferon-producing cells in human blood
35. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon
36. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology
37. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T cells stimulatory activity by IFN-α
38. Interferon α in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia
39. GM-CSF can improve the cytogenetic response obtained with interferon-α therapy in patients with chronic myelogenous leukemia
40. Endogenous type I interferons as a defense against tumors
41. Production of interferon by peripheral-blood mononuclear cells from normal individuals and patients with chronic lymphocytic leukemia
42. Lymphocyte-mediated immunosurveillance of epithelial cancers?
43. Modulation of interleukin-18 expression in human colon carcinoma: Consequences for tumor immune surveillance
44. Eastern cooperative study of interferon γ in metastatic melanoma: An innovative study design
45. + T-cell tolerance to T-cell priming through in vivo ligation of CD40
46. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
47. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection
48. A symbiotic concept of autoimmunity and tumour immunity: Lessons from vitiligo
49. Coupling and uncoupling of tumor immunity and autoimmunity
50. Interferon α (IFN-α) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC)
51. Induction of bystander T-cell proliferation by viruses and type I interferon in vivo
52. + T cells after injection of tumor cells expressing IFN-α into syngeneic mice
53. Type I interferons keep activated T cells alive
54. Interleukin-15: Biology and relevance to human disease
55. Interleukin-15 skews monocyte differentiation into dendritic cells with features of Langerhans cells
56. Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice
57. NK-cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: Immunogene therapy using a highly secretable form of interleukin-15 gene transfer
58. Immunogene therapy of murine fibrosarcoma using IL-15 gene with high translation efficiency
59. Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo
60. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: Effects on tumorigenicity, metastatic potential and immune response
61. The combined action of IL-15 and IL-12 gene transfer can induce tumor-cell rejection without T- and NK-cell involvement
62. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu
63. Danger signals: SOS to the immune system
64. Heat-shock proteins refine the danger theory